| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 1/6 |
Life Science REIT plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.39 |
| 52 Week High | UK£0.77 |
| 52 Week Low | UK£0.37 |
| Beta | 0.13 |
| 1 Month Change | -14.25% |
| 3 Month Change | -39.27% |
| 1 Year Change | -36.89% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -61.69% |
Recent News & Updates
Recent updates
Shareholder Returns
| LABS | GB Health Care REITs | GB Market | |
|---|---|---|---|
| 7D | -2.0% | -3.1% | -0.5% |
| 1Y | -36.9% | -14.6% | 0.4% |
Rentabilidad frente al sector: LABS obtuvo unos resultados inferiores a los del sector UK Health Care REITs , que el año pasado arrojó un rendimiento del -17%.
Rentabilidad vs. Mercado: LABS obtuvo unos resultados inferiores a los del mercado UK, que fue del -5.3% el año pasado.
Price Volatility
| LABS volatility | |
|---|---|
| LABS Average Weekly Movement | 3.6% |
| Health Care REITs Industry Average Movement | 3.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.2% |
| 10% least volatile stocks in GB Market | 2.6% |
Precio estable de las acciones: El precio de las acciones de LABS ha sido volátil en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de LABS (3%) se ha mantenido estable durante el año pasado.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Simon Farnsworth | https://www.lifesciencereit.co.uk |
Life Science REIT plc Fundamentals Summary
| LABS fundamental statistics | |
|---|---|
| Market cap | UK£134.75m |
| Earnings (TTM) | -UK£21.71m |
| Revenue (TTM) | UK£19.94m |
6.8x
P/S Ratio-6.2x
P/E RatioIs LABS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LABS income statement (TTM) | |
|---|---|
| Revenue | UK£19.94m |
| Cost of Revenue | UK£6.12m |
| Gross Profit | UK£13.83m |
| Other Expenses | UK£35.53m |
| Earnings | -UK£21.71m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.062 |
| Gross Margin | 69.33% |
| Net Profit Margin | -108.85% |
| Debt/Equity Ratio | 38.0% |
How did LABS perform over the long term?
See historical performance and comparison